Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods Under Section 41

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, governs the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood products. This Act aims to ensure that therapeutic goods are of acceptable quality, safety, and efficacy, thereby protecting public health. The publication of the list of manufacturers revoked from licensing for the manufacture of therapeutic goods is a measure under this Act to maintain regulatory oversight and compliance within the industry. The revocation of licences, as announced by Katherine Clark, a delegate of the Secretary of the Department of Health, Therapeutic Goods Administration, is a response to manufacturers requesting to be removed from the licensing framework. This action highlights the Act's flexibility in accommodating manufacturers while ensuring that the standards set by the Therapeutic Goods Administration are upheld.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, importation, and advertising of therapeutic goods in Australia. This Act is administered by the Therapeutic Goods Administration (TGA) under the Department of Health, and it aims to regulate therapeutic goods to ensure their quality, safety, and efficacy. The revocation of a Licence to Manufacture Therapeutic Goods under section 41(1)(d) of the Act applies to specific entities that have had their manufacturing licences revoked at their own request. In this instance, the Act affects the manufacturers listed in the gazette, namely the WA Hospitals Central Pharmaceutical Manufacturing Facility trading as AUSPMAN, Annex Holdings Pty Ltd trading as Annex Industries, and Orchard Manufacturing Co Pty Ltd. This revocation affects these entities' ability to manufacture therapeutic goods within Australia, impacting their operations and compliance with the Act. The Act has a national jurisdictional reach, applying to all therapeutic goods throughout Australia, regardless of state or territory. It includes provisions for the regulation of all aspects of therapeutic goods, from initial manufacturing to final distribution and advertising. The Act does not specify any exclusions or exemptions for the revocation of manufacturing licences; rather, it provides a clear process for the TGA to revoke licences upon request by the manufacturer. While the primary Act governs these activities, the TGA can extend or restrict application through subordinate instruments, such as regulations and guidelines, which provide further detail on specific aspects of therapeutic goods regulation.

Key Provisions

The main sections of the Therapeutic Goods Act 1989 referenced in the document involve the revocation of a licence to manufacture therapeutic goods. Specifically, section 41(1)(d) provides the Secretary with the authority to revoke a licence by notice in writing. This is exercised here with regard to three manufacturers: WA Hospitals Central Pharmaceutical Manufacturing Facility T/A AUSPMAN, Annex Holdings Pty Ltd T/A Annex Industries, and Orchard Manufacturing Co Pty Ltd. These revocations were carried out at the request of the manufacturers themselves. The Therapeutic Goods Act 1989 imposes certain obligations on the parties it governs, primarily concerning the quality and safety of therapeutic goods. Manufacturers must comply with strict regulations to ensure that their products meet required standards. This includes maintaining proper documentation, adhering to good manufacturing practices, and ensuring that their facilities are inspected and approved by the Therapeutic Goods Administration (TGA). The revocation of a licence indicates a failure to meet these obligations, which may arise from non-compliance with regulatory standards or other reasons deemed sufficient by the TGA. Breaching the requirements of the Therapeutic Goods Act 1989 can lead to significant consequences. While the specific offences and penalties are not detailed in this notice, the Act generally provides for both civil and criminal penalties. Civil penalties can include fines, while criminal penalties can result in imprisonment. For example, section 33DA of the Act imposes penalties for manufacturing therapeutic goods that do not comply with the standards set by the TGA, with maximum penalties including fines of up to $1,650,000 for corporations and imprisonment for up to 10 years for individuals. Additionally, repeated or serious breaches may lead to further actions, such as ongoing monitoring or additional revocations of licences.